Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Florian M. Karl1,2*, Rolf Holle1, Robert Bals3, Timm Greulich4, Rudolf A. Jörres5, Annika Karch6, Armin Koch6, Stefan Karrasch5,7, Reiner Leidl1, Holger Schulz7, Claus Vogelmeier4, Margarethe E. Wacker1 and for the COSYCONET Study Group

Abstract

Background: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease.

Methods: Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared between 131 AATD patients (106 with, 25 without augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the COSYCONET COPD cohort. The medication costs of AT were excluded from all analyses to reveal differences associated with morbidity profiles. The association of AATD (with/without AT) with costs or HRQL was examined using generalized linear regression modelling (GLM) adjusting for age, sex, GOLD grade, BMI, smoking status, education and comorbidities.

Results: Adjusted mean direct annual costs were €6,099 in AATD patients without AT, €7,117 in AATD patients with AT (excluding costs for AT), and €7,460 in COPD patients without AATD. AATD with AT was significantly associated with higher outpatient (+273%) but lower inpatient (−35%) and medication costs (−10%, disregarding AT) compared with COPD patients without AATD. There were no significant differences between groups regarding indirect costs and HRQL.

Conclusion: Apart from AT costs, AATD patients tended to have lower, though not significant, overall costs and similar HRQL compared to COPD patients without AATD. AT was not associated with lower costs or higher HRQL.

Trial registration: NCT01245933

Keywords: COPD, Alpha-1-Antitrypsin Deficiency, Direct costs, Indirect costs, Health-related quality of life, Augmentation therapy

Background

Alpha-1-antitrypsin (AAT) is an anti-protease that protects tissues – mainly lung parenchyma – from damage by enzymes released from inflammatory cells. Thus a deficiency of AAT can lead to uninhibited lung parenchymal destruction and the development of chronic obstructive pulmonary disease (COPD), particularly lung emphysema [1]. There are about 100 different genetic mutations leading to dysfunction of AAT or Alpha-1-antitrypsin deficiency (AATD) [2] which is also associated with liver cirrhosis [3] and over-expression of pro-apoptotic pathways [4].

AATD is a very rare but also highly underdiagnosed disease [5, 6]. The prevalence of deficiency related alleles (PI*ZZ and PI*SZ) in the world population is estimated to be 0.1% for the PI*ZZ and 0.7% for the PI*SZ genotype [7]. However, assessment of the true prevalence is difficult, as there are no population-based, large-scale screening studies [1], due to the difficulties of conducting population-based studies, poor awareness of the disease, perceived lack of treatment efficacy, and complexity of testing algorithms [8, 9].
COPD patients with underlying AATD differ from COPD patients without this deficiency e.g. with regard to smoking history, comorbidities and exercise-related desaturation in arterial blood [10, 11]. However, standard COPD therapy is recommended for AATD patients [12]. Comorbidities, which have been identified as a major driver of excess costs as well as of loss in health-related quality of life (HRQL) in COPD patients [13, 14], may differ between patients with and without AATD.

Therefore, the aim of this cross-sectional analysis was to compare the annual direct and indirect costs as well as generic and disease-specific HRQL between COPD patients with and without AATD. To our knowledge, this has not yet been done before in a large-scale study. To identify costs related to (co-)morbidty profiles in AATD compared to non-AATD patients, the tremendous cost bias from alpha-1-proteinase inhibitor augmentation therapy (AT) was circumvented by excluding these costs from the analysis. As there is an ongoing controversy about the efficacy of AT therapy [1, 15], we also examined differences regarding (non-AT) direct and indirect costs and HRQL between augmented and non-augmented AATD patients.

Methods
Data and study design
Data was obtained from the baseline examination of the German multicentre COPD cohort COSYCONET (German COPD and Systemic Consequences – Comorbidities Network). The study included 2,741 subjects with a clinical diagnosis of COPD. Recruitment took place in 31 study centres between September 2010 and December 2013. Participants had to be ≥40 years of age and stable. Detailed information on recruitment and exclusion criteria can be found in Karch et al. [16]. COPD was defined according to the GOLD criteria after performing standardized post-bronchodilator spirometry [17]. For GOLD staging, reference values according to the Global Lung Initiative (GLI) were used [18]. 450 subjects with a Tiffeneau index above 70% at baseline examination were excluded from this analysis (Fig. 1).

AATD patients were identified by using self-reports on AATD and its genotype, AT from the medication list and the measured AAT serum levels. Participants with the heterozygous genotype PiMZ were classified as COPD patients without AATD. If a person answered that they did not know his or her genotype and was not receiving AT,
an AAT serum level cut-off-point of <50 mg/dl was selected to distinguish COPD patients with and without AATD. With n = 131 patients (6.0%), including 106 patients with AT and 25 without AT, AATD was overrepresented in COSYCONET (Fig. 1).

Healthcare utilisation, work absenteeism and calculation of costs
Healthcare utilisation was assessed using standardised questionnaires and interviews. The calculation of costs has been described previously [14]. In brief, outpatient physician visits (last 3 months, subdivided by 13 specialists), and physiotherapist visits, rehabilitation and days spent in hospital (past 12 months) were considered for the calculation of direct healthcare costs. These quantities were multiplied by the German unit costs (Additional file 1) of the year 2012 [19]. Furthermore, currently used prescribed pharmaceuticals were considered. Utilization of pharmaceuticals was estimated based on patients' information on the drug code, defined daily doses [20] and German pharmacy retail prices of the year 2012 [21]. For the calculation of costs per year all costs were extrapolated to 12 months. In case of augmented AATD patients, the estimated mean annual costs of AT, €72,255 [21], were subtracted from the medication costs. Indirect costs as a consequence of production losses [22] included the temporary inability to work and premature retirement for participants aged < 65 years. For cost calculations the human capital approach was applied that accounts full labour costs for all sick days (€177 per missed day in 2012) [22]. Premature retirement (<65 years) was valued with mean annual labour costs of €37,126 per year [23]. As there is an ongoing discussion about the appropriate valuation of indirect costs [22], the friction cost approach was additionally applied. This means, that missed working days were calculated at only €142 and only for the first 50 days of work absenteeism, and costs for premature retirement were omitted [24].

Health-related quality of life
Participants completed the Saint-George’s Respiratory Questionnaire (SGRQ) [25] and the COPD Assessment Test (CAT) [26]. The scoring of the SGRQ ranges from 0 to 100 whereas CAT ranges from 0 to 40 with higher scores indicating worse HRQL [25, 26]. The generic EuroQol 5 dimensions (EQ-5D-3 L) questionnaire including Visual Analogue Scale (VAS) was used in addition as an established German EQ-5D-3 L utility tariff [27]. This has been demonstrated as suitable for cost-utility analyses [28]. In both parts of the EQ-5D-3 L, higher values are associated with a better HRQL.

Comorbidities
Participants were asked: “Has a physician ever diagnosed you with one of the following diseases?”. Thereby information on 33 pre-defined comorbidities was assessed. Comorbidities were added up to a comorbidity count. Such a count has been shown to perform well in quantifying comorbidity in COPD patients [29].

Statistical analysis
For comparing characteristics between AATD patients and COPD control subjects, or between the two subgroups of AATD patients, t-tests for continuous, Chi²-tests for categorical variables, and Wilcoxon signed-rank tests for ordinal variables were applied.

The association of AATD and AT with direct and indirect costs was examined via generalised linear regression modelling (GLM). The covariates GOLD grade 1–4, age, sex, school education, smoking status, BMI and comorbidity count were added to the model. As cost data was highly right-skewed, which means that costs only assume values ≥0 and more individuals have costs below the mean than above, a gamma model with log-link was assumed. In the case of indirect costs only participants aged younger than 65 years were included. Participants with zero-costs were assigned €1 for regression modeling. Resulting cost estimates can be directly interpreted as factors. Adjusted means in direct and indirect costs were estimated as recycled predictions from 1000 bootstrap replications [30]. GLM with normal distribution was performed for HRQL scores. Therefore, estimates for HRQL represent additional units on the HRQL scale.

Statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA, version 9.3). For significance testing, a p-value of 0.05 or less was required. Graphics were edited in R [31] using the package ggplot2 [32].

Sensitivity analysis
To consider potential residual confounding due to the categorization of lung function in GOLD grades 1 to 4, GLM was also performed using the exact predicted percentage of Forced Expiratory Volume in 1 second (FEV₁ %pred.) instead of GOLD grades [18].

Ethics statement
The COSYCONET study was approved by the Ethics Committees of the local study centres. All participants gave their written informed consent.

Results
Characteristics of the study population
Data of 2049 COPD patients without AATD and 131 with AATD (106 with AT and 25 without AT) were included in the analysis. Their characteristics are given in Table 1.
AATD patients were significantly younger (60.3 vs. 65.4 years, \( p < 0.001 \)) and in higher GOLD grades than the COPD patients without AATD (\( p = 0.01 \)), but showed a lower number of comorbidities (3.1 vs. 3.9, \( p < 0.001 \)). Furthermore, AATD patients had a higher proportion of never-smokers (23.7% vs. 5.4%, \( p < 0.001 \)) and a lower BMI (24.7 vs. 26.8 kg/m\(^2\), \( p < 0.001 \)). Comparing AATD patients receiving AT with AATD patients not receiving AT, significant differences regarding the distributions of GOLD grades and gender were found (Table 1).

### Table 1 Characteristics of the study population

| Subgroups          | A          | B          | B1         | B2          | p-value        |
|--------------------|------------|------------|------------|------------|----------------|
|                    | Subgroups  |            |            |            | A vs. B        |
|                    |            |            | B1 vs. B2  |            |                |
| N                  | 2049       | 131        | 106        | 25         |                |
| Age (years)        | 65.4 (8.2) | 60.3 (10.0)| 59.6 (9.9) | 63.1 (10.2)| <.001\(^a\)|.12\(^a\) |
| % Age < 45 years   | 1.0        | 3.8        | 3.8        | 4.0        | <.001\(^b\)|.63\(^b\) |
| % Age 45–55 years  | 9.1        | 29.0       | 30.19      | 24.0       |                |
| % Age 56–65 years  | 33.6       | 29.8       | 31.1       | 24.0       |                |
| % Age 66–75 years  | 44.1       | 31.3       | 30.2       | 36.0       |                |
| % Age > 75 years   | 12.1       | 6.1        | 4.72       | 12.0       |                |
| Gender             |            |            |            |            |                |
| % Males            | 61.1       | 56.5       | 62.3       | 32.0       | .30\(^b\) |.01\(^b\) |
| COPD GOLD Grade    |            |            |            |            | .01\(^b\) | <.001\(^b\) |
| % Grade 1 (FEV\(_1\)% pred. \( \geq \) 80%) | 9.0 | 4.6 | 4.7 | 4.0 |                |
| % Grade 2 (50 \( \leq \) FEV\(_1\)% pred. < 80) | 42.3 | 34.4 | 24.5 | 76.0 |                |
| % Grade 3 (30 \( \leq \) FEV\(_1\)% pred. < 50) | 38.1 | 42.8 | 50.9 | 8.0 |                |
| % Grade 4 (FEV\(_1\)% pred. < 30) | 10.5 | 18.3 | 19.8 | 12.0 |                |
| Education          |            |            |            |            | <.001\(^b\) | .86\(^b\) |
| % Basic school education | 57.0 | 32.1 | 33.0 | 28.0 |                |
| % Secondary school education | 26.0 | 43.5 | 42.5 | 48.0 |                |
| % Higher school education | 17.0 | 24.4 | 24.5 | 24.0 |                |
| Smoking status     |            |            |            |            | <.001\(^b\) | .25\(^b\) |
| % Never smokers    | 5.4        | 23.7       | 20.8       | 36.0       |                |
| % Former smokers   | 69.2       | 75.6       | 78.3       | 64.0       |                |
| % Smokers          | 25.4       | 0.7        | 0.9        | 0.0        |                |
| BMI (kg/m\(^2\))   | 26.8 (5.3) | 24.7 (4.0) | 24.6 (4.1) | 24.8 (3.6) | <.001\(^a\) | .85\(^a\) |
| % Normal weight (18.5 \( \leq \) BMI < 25) | 35.7 | 52.7 | 52.8 | 52.0 |                |
| % Overweight (25 \( \leq \) BMI < 30) | 37.1 | 33.6 | 32.1 | 40.0 | <.001\(^b\) | .64\(^b\) |
| % Obese (BMI \( \geq \) 30) | 23.7 | 9.9 | 10.4 | 8.0 |                |
| % Underweight (BMI < 18.5) | 3.5 | 3.8 | 4.7 | 0.0 |                |
| Comorbidities      |            |            |            |            |                |
| Count              | 3.9 (2.6)  | 3.1 (2.5)  | 3.0 (2.5)  | 3.4 (2.3)  | <.001\(^c\) | .30\(^c\) |
| % Liver cirrhosis  | 1.3        | 1.5        | 1.9        | 0.0        | .68\(^b\) | .49\(^b\) |
| % Hepatitis        | 5.4        | 6.9        | 8.5        | 0.0        | .48\(^b\) | .13\(^b\) |

Data are mean (standard deviation) or percentage (%)

A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B = COPD patients with AATD, B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT

\(^a\) p-value based on t-test, \(^b\) p-value based on Chi\(^2\)-test, \(^c\) Wilcoxon signed rank test

Unadjusted healthcare utilisation, work absence and retirement

AATD patients, compared to COPD patients without AATD, had about twice as many outpatient visits, a lower percentage of hospitalizations (24% vs. 39%), a shorter duration of stay at inpatient services, and a lower number of prescribed medication (excluding AT) (Table 2). Also, AATD patients had less sick days and a lower proportion of premature retirement than COPD patients without AATD.
Table 2 | Unadjusted healthcare utilization, costs and health-related quality of life

| Healthcare utilization          | Subgroups       | A (n = 2049) | B (n = 131) | B1 (n = 106) | B2 (n = 25) |
|--------------------------------|-----------------|-------------|-------------|-------------|-------------|
| Outpatient services (3 months) |                 |             |             |             |             |
| % User                         |                 | 76          | 66          | 64          | 76          |
| Number of visits               |                 | 1.9 (2.3)   | 3.8 (4.8)   | 4.1 (5.0)   | 2.7 (3.7)   |
| Specialists                    |                 | 94          | 96          | 96          | 96          |
| Number of visits               |                 | 4.4 (4.4)   | 8.9 (7.4)   | 9.6 (7.0)   | 5.9 (8.5)   |
| Ambulant hospital visits       |                 | 16          | 18          | 18          | 16          |
| % User                         |                 | 0.3 (1.5)   | 0.7 (3.0)   | 0.8 (3.3)   | 0.2 (0.4)   |
| Inpatient services (12 months) |                 |             |             |             |             |
| % User                         |                 | 39          | 24          | 24          | 24          |
| Number of visits               |                 | 0.6 (1.1)   | 0.3 (0.8)   | 0.4 (0.9)   | 0.3 (0.5)   |
| Duration of stay               |                 | 5.8 (14.1)  | 2.3 (5.8)   | 2.2 (5.7)   | 2.7 (6.3)   |
| Rehabilitation (12 months)     |                 |             |             |             |             |
| Ambulant                       |                 | 2           | 4           | 3           | 8           |
| Number of visits               |                 | 0.5 (4.2)   | 0.6 (3.1)   | 0.5 (2.8)   | 1.16 (4.0)  |
| Stationary                     |                 | 14          | 21          | 22          | 16          |
| Duration of stay               |                 | 3.3 (8.8)   | 5.2 (10.9)  | 5.4 (10.6)  | 5.0 (12.3)  |
| Physiotherapist (12 months)    |                 | 35          | 52          | 51          | 56          |
| % User                         |                 | 7.1 (18.5)  | 15.2 (23.6) | 15.2 (24.1) | 14.9 (22.1) |
| Number of visits               |                 | 6.1 (3.2)   | 4.7 (2.7)   | 4.7 (2.6)   | 4.4 (3.1)   |
| Medication (7 days)            |                 |             |             |             |             |
| Number of prescribed medications (without AT) | | 938 (834) | 2160 (1547) | 2423 (1559) | 1044 (857) |
| Direct costs (12 months)       |                 |             |             |             |             |
| Outpatient costs               |                 | 3441 (8302) | 1341 (3394) | 1285 (3337) | 1579 (3687) |
| Inpatient costs                |                 | 433 (1086)  | 674 (1327)  | 675 (1293)  | 666 (1487)  |
| Rehabilitation                 |                 | 118 (307)   | 252 (393)   | 253 (400)   | 247 (368)   |
| Physiotherapist                |                 | 2533 (3327) | 1961 (1076) | 2056 (1080) | 1558 (976)  |
| Medication costs               |                 | 2533 (3327) | 60427 (28718) | 74311 (1080) | 1558 (976) |
| Medication costs including AT  |                 | 7446 (9836) | 6374 (4535) | 6675 (4202) | 5096 (5555) |
| Total direct costs             |                 | 7446 (9836) | 64840 (29467) | 78930 (4202) | 5096 (5555) |
| Indirect costs (participants < 65 years) | | A (n = 897) | B (n = 82) | B1 (n = 69) | B2 (n = 13) |
| Work absenteeism (12 months)   |                 |             |             |             |             |
| % retired                      |                 | 47          | 35          | 37          | 23          |
| % employed                     |                 | 38          | 55          | 54          | 62          |
| % thereof with sick days (12 months) | | 73          | 67          | 59          | 100         |
AATD patients receiving AT compared to AATD patients not receiving AT visited a general practitioner or specialist about two times more often and had a higher rate of premature retirement (37% vs. 23%). It has to be noted that the number of outpatient visits of AT receiving AATD patients did most likely include visits for AT application as information on the purpose of visits was missing.

**Association of AATD and AT with direct and indirect costs**

All cost estimates considered in the following analyses exclude the costs of AT therapy; thus estimated mean annual costs of approximately €72,000 [21] have to be added in patients receiving AT.

Table 3 shows the major results of regression models for costs. Adjusted for possible confounders, there were no significant associations of AATD (with or without AT) with total direct costs. However, AATD patients with AT showed significantly higher annual outpatient costs (factor 2.7, \( p < 0.001 \)) compared to patients without AATD. Conversely, AT-receiving patients had lower inpatient costs (−35%, \( p = 0.02 \)). Medication costs, excluding AT costs, were decreased by 10% (\( p = 0.11 \)) and 28% (\( p = 0.01 \)) in AATD patients with and without AT, respectively. As stated before, these results were not adjusted for the reason of consultation. Therefore, the number of outpatient visits in AATD patients with AT may include a number of visits that were exclusively due to AT administration. There were no significant associations of AATD with indirect cost neither for the human capital nor the friction cost approach. Complete regression results are shown in Additional file 2.

Adjusted mean annual direct and indirect costs are shown in Table 4. Total annual direct costs due to healthcare, were highest in COPD patients without AATD (€7460 [€7026 – €7924]) and lowest in patients with AATD but without AT (€6099 [€6288 – €8256]). AATD patients with AT had mean annual direct cost of €7117 (€6029 – €8392). The categories of direct costs, in relation to the total amount of direct costs in the three subsamples, are illustrated in Fig. 2. Inpatient costs contributed most to the total healthcare costs in COPD patients without AATD (€3586 [€3201 – €4010]) and AATD patients without AT (€2338 [€561 – €5288]). Most cost driving category in AATD patients with AT was outpatient costs (€2570 [€2256 – €2866]).

**Comparison of HRQL in the three subgroups**

There were no significant differences regarding HRQL between the groups. In particular, having AATD with or without AT was not associated with differences in CAT, SGRQ, EQ-5D-3 L utility or EQ-5D VAS compared to patients without AATD. Results from regression analyses are shown in Table 5; detailed regression results can be found in Additional file 3. Adjusted mean HRQL scores are provided in Fig. 3.

**Result of sensitivity analysis**

Using FEV\(_1\) in terms of the exact %predicted instead of GOLD grades 1 to 4 for adjustment in regression models did not affect the association between patient groups and costs or HRQL. Thus there is no indication of residual
confounding by using the GOLD grades 1 to 4 instead of the continuous variable FEV1%pred. Details are shown in Additional files 4 and 5.

Discussion

This study compared costs and HRQL between COPD patients with AATD (with or without AT) and COPD patients without this deficiency. Costs of AT therapy (about €72,000 per year [21]) were excluded in order to identify the healthcare costs as a function of the patient group. AATD patients, both with and without AT, tended to have lower total costs compared to COPD patients without AATD, but these differences did not reach statistical significance. Accordingly, most of the single cost categories also did not show significant differences. However, adjusted mean medication costs were significantly lower in both AATD patient groups compared to COPD patients without AATD. Outpatient costs were considerably increased in AATD patients with AT, while inpatient costs were lower. There were no differences found between the groups regarding indirect costs or HRQL.

A recent study by Greulich et al. [33] that examined German claims data of about 2.8 million insurants over a time period of four years conducted an age- and gender-matched (1:10) comparison between 5,900 COPD patients without AATD and 590 COPD patients with AATD. AATD patients had more outpatient consultations and a higher hospitalization rate compared to COPD patients without AATD [33]. These results were not adjusted for disease severity or stratified by AT which might explain the, compared to our results, opposite finding regarding the hospitalization rate of AATD patients. With respect to the higher frequency of outpatient service consultation in AATD patients, Greulich et al., like us, point out that this is at least in part explainable by AT application [33].

Another study by Zacherle et al. using US claims data also found significantly more inpatient visits in AATD patients compared to COPD patients without

| Table 3 | Results of regression models: Association of AATD and AT with annual direct and indirect costs |
|---|---|---|---|---|---|---|---|
| Costs | Direct costs | Indirect costs |
| | Total direct costs | Outpatient costs | Inpatient costs | Medication costs | Other costs | HC | FC |
| Group | A | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| B1 | 0.95 (0.80 – 1.12) | 2.73 (2.35 – 3.17) | 0.65 (0.45 – 0.94) | 0.90 (0.79 – 1.03) | 1.14 (0.81 – 1.61) | 1.05 (0.79 – 1.39) | 0.94 (0.66 – 1.35) |
| B2 | 0.80 (0.57 – 1.13) | 1.13 (0.84 – 1.51) | 0.79 (0.39 – 1.63) | 0.72 (0.56 – 0.93) | 1.23 (0.65 – 2.34) | 0.67 (0.38 – 1.18) | 1.18 (0.67 – 2.08) |

A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT

Indirect costs only include patients < 65 years of age

Significant estimates on a level of p < .05 are printed bold

Other costs include Physiotherapist and Rehabilitation costs

HC Human capital approach, FC Friction costs approach

Total direct costs and medication costs do not include AT costs of approximately €72,000

| Table 4 | Adjusted annual direct and indirect costs |
|---|---|---|---|---|
| Adjusted mean annual costs (€) | Direct costs | Total | Outpatient costs | Inpatient costs |
| % zero costs | 0% | 0% | 62% | 0% |
| Group | A | 7460 [7026 – 7924] | 937 [902 – 973] | 3586 [3201 – 4010] | 2522 [2381 – 2663] | 566 [513 – 628] |
| B1 | 7117 [6029 – 8392] | 2570 [2256 – 2866] | 1715 [740 – 3076] | 2144 [1903 – 2409] |
| B2 | 6099 [4288 – 8256] | 1061 [763 – 1414] | 2338 [561 – 5288] | 1805 [1388 – 2261] |
| Adjusted mean annual costs (€) | Indirect costs | Human capital approach | Friction costs approach |
| % zero costs | 26% | 72% |
| Group | A | 19,583 [18,451 – 20,803] | 981 [839 – 1138] |
| B1 | 18,813 [13,632 – 24,716] | 1276 [608 – 2181] |
| B2 | 16,171 [6194 – 28,316] | 1866 [633 – 3764] |

A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT

Significant estimates on a level of p < 0.05 are printed bold. Indirect costs only include participants < 65 years of age

Totals direct costs and medication costs do not include AT costs of approximately €72,000
AATD (58% vs. 19.5%) leading to an increase by $US27,674 in total healthcare costs per patient [34]. However, this study included the AT costs of AT-receiving AATD patients (13% in the sample) and was not adjusted for differences in COPD severity. In another US survey Mullins et al. performed a cost analysis on AATD patients in 2003 and identified mean costs per year for hospitalization, outpatient services and prescription of drugs (other than AT) of $US4,497, $US2,299, and $US6,456, respectively [35]. These costs are higher than the costs estimated for the COSYCONET dataset. The differences could be due to a lack of adjustment for case severity and to national cost differences. In COSYCONET, indirect costs did not show significant differences between COPD patients with and without AATD. However, Zacherle et al. found COPD patients without AATD to receive disability benefits twice as often as AATD patients (40.1% vs. 20.3%, \( p < 0.001 \)) [34]. To the knowledge of the authors, the present study is the first one comparing indirect costs in COPD patients with and without AATD in a comprehensive manner.

After stratification of AATD patients for AT, some differences appeared regarding single direct cost factors. Patients receiving AT showed considerably increased outpatient but decreased inpatient costs

**Table 5** Results of regression models: Regression coefficients of AATD patients with and without AT

| HRQL   | SGRQ | CAT | EQ-SD-3 L utility | EQ-SD VAS |
|--------|------|-----|------------------|----------|
| Group  | A Ref. | B1 | 2.68 (−0.82 – 6.19) | 0.66 (−0.73 – 2.04) | −0.55 (−4.45 – 3.35) | −1.58 (−5.23 – 2.07) |
|        |       | B2 | −0.64 (−7.53 – 6.24) | 0.60 (−2.09 – 3.31) | −1.67 (−9.34 – 6.00) | 2.14 (−5.01 – 9.30) |

Group A = COPD patients without Alpha-1-antitrypsin deficiency (AATD). Group B1 = COPD patients with AATD and augmentation therapy (AT). B2 = COPD patients with AATD but without augmentation therapy. EQ-SD-3 L utility was multiplied by 100.

Significant estimates on a level of \( p < 0.05 \) are printed bold.
compared to COPD patients and AATD patients not receiving AT. Other studies relevant for inpatient or outpatient costs examined exacerbation rates or FEV$_1$ and showed inconsistent or not significant results [15]. The increase of outpatient costs in patients receiving AT in our study is at least partially explainable by the AT itself which is usually administered by a weekly intravenous infusion in the outpatient setting. As we did not have information on the reason for individual physician visits, these costs could not be specified in our analysis. Conversely, the decreased inpatient and medication costs might be a beneficial side-effect of the more frequent outpatient visits associated with the AT. The more frequent visits at outpatient services might lead to a better adherence to self-management plans and compliance to medication plans. Furthermore, they might facilitate the early detection of changes in needs and clinical picture of the patients and therefore prevent hospitalisation. This effect may also, at least partially, explain the overall although not significant lower costs in AATD patients.

Our finding that HRQL did not differ between COPD patients with and without AATD is in line with former research by Manca et al. who did not find HRQL differences between AATD patients and COPD patients without AATD, regarding CAT,EQ-5D-3 L and EQ-5D VAS [36]. HRQL also did not differ between AATD patients with and without AT. Similar results were found in a randomized, placebo-controlled trial by Chapman et al. [37] in which SGRQ values did not differ significantly (44.3 vs. 42.4, $p = 0.91$) between AATD patients with and without AT. The results presented in the review by Gotzsche et al. also suggest no clinically relevant differences in HRQL [41].

When considering the cost reductions due to less usage of inpatient services and prescribed medication in AT-receiving AATD patients, it has to be kept in mind that these patients cause very high total annual costs of about €72,000 due to augmentation therapy. Our study shows that this amounts for about 91% of the total direct costs in AATD patients receiving AT. In our opinion, the finding that HRQL did not differ between AATD patients with AT and COPD patients without AATD does not allow conclusions about the effect of AT on HRQL. In particular AATD patients not receiving AT could not serve as a control group for AT-receiving AATD patients, as we did not have access to the detailed information that had led to the prescription of AT. The AATD patients without AT were older and had less severe COPD compared to AATD patients with AT. This could be partly...
explained by therapeutic guidelines, which indicate to prescribe AT only in severe cases with minimal smoking history [38]. Nevertheless, our results underline how important information on treatment effects of AT on HRQL of AATD patients is both medically and economically. Thus clarification of the (cost-) effectiveness of AT should have high priority in AATD research.

There have been several efforts to estimate the cost effectiveness of AT, however with inconsistent results [39, 40]. From the perspectives of both health economics and morbidity profiling it is of interest whether the costs of standard COPD therapy depend on the presence of AATD and the use of AT. We provide such data regarding single direct and indirect cost factors, and the results can be used as more precise estimators of yearly costs in the three patient groups.

Recently there has been new supporting evidence for the effectiveness of AT in AATD therapy by a randomized clinical trial [41]. However, our finding of indifferent costs also raises the question how a potentially intensified but standard COPD therapy compares with additional AT and which long-term health and cost benefits might be associated with these options. Due to AATD patients often being excluded from pharmacologic trials on COPD therapy, there is actually a lack of evidence on the impact of standard therapy on this patient group.

The strength of the study is based on a sample size that enabled us to include sufficient numbers of patients in all three patient groups, with respect to the rarity of AATD. Furthermore, the COSYCONET COPD cohort acquired detailed information to analyse direct and indirect costs, as well as generic and disease-specific HRQL. There are, however, also limitations. The analysis of healthcare utilisation relied on self-reported questionnaires, with the risk of recall bias. However, there were no hints for differential biases between groups. Some healthcare services such as nursing, medical aids and appliances were not considered in the cost calculations. Finally, in this cross-sectional study only statistical associations could be explored. Despite the limitations it is reasonable to assume that the estimates derived from the baseline visit of COSYCONET give a realistic picture of direct and indirect costs as well as of the HRQL in COPD with and without AATD and AT.

**Conclusion**

If AT costs were excluded, AATD patients tended to show lower, but not significant, overall costs and similar HRQL compared to COPD patients without AATD. AT was not associated with lower costs or higher HRQL from a cross-sectional perspective.

**Additional files**

**Additional file 1:** German unit costs according to Bock et al. [19]. Indirect costs only for subjects of employable age < 65 years. Work absence only for full-time and regular part-time employees. (DOC 40 kb)

**Additional file 2:** Indirect costs only include participants < 65 years of age. Significant estimates on a level of p < .05 are printed bold. A = COPD patients without AATD, B1 = COPD patients with Alpha-1-antitrypsin deficiency (AATD) and augmentation therapy (AT), B2 = COPD patients with AATD but without AT. Other costs include physiotherapist and rehabilitation costs. (DOC 68 kb)

**Additional file 3:** Significant estimates on a level of p < .05 are printed bold. A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT. EQ-5D-3 L values are given after multiplication by 100. (DOC 47 kb)

**Additional file 4:** Indirect costs only include participants < 65 years of age. Significant estimates on a level of p < .05 are printed bold. A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT. Other costs include physiotherapist and rehabilitation costs. There was no relevant impact of the change in the model on the estimates of the different groups. (DOC 28 kb)

**Additional file 5:** Significant estimates on a level of p < .05 are printed bold. A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT. (DOC 29 kb)

**Abbreviations**

AATD: Alpha-1-Antitrypsin Deficiency; AT: Augmentation Therapy; BMI: Body Mass Index; CAT: COPD Assessment Test; COPD: Chronic Obstructive Pulmonary Disease; COSYCONET: German COPD and Systemic Consequences – Comorbidities Network; EQ-5D-3 L: EuroQol 5 dimensions, 3 level version; FEV1: Forced Expiratory Volume in 1 second; GOLD: Global Initiative for Chronic Obstructive Pulmonary Disease; HRQL: Health-related quality of life; SGRQ: Saint-George’s Respiratory Questionnaire; VAS: Visual Analogue Scale.

**Acknowledgments**

Not applicable.

**Funding**

This work was supported by the Competence Network Asthma and COPD (ASCONET). The COSYCONET COPD Cohort is funded by the German Federal Ministry of Education and Research (BMBF) with grant numbers 01GI0881 and 01GI0882, as well as by unrestricted grants from several pharmaceutical companies.

**Availability of data and materials**

The full dataset supporting the conclusions of this article is available upon request and application from the Competence Network Asthma and COPD (ASCONET, https://www.asconet.net/html/cosyconet/projects).

**Authors’ contributions**

FK, MW and RH conceptualized the paper. FK, MW, and RH performed the statistical analysis and FK, MW, RL, TG and RH interpreted the data. FK and MW drafted the manuscript. RB, RAJ, AKA, AKO, HS, and CV were involved in the coordination and the data acquisition of the COSYCONET study. All authors critically reviewed each draft of the manuscript and approved the final manuscript.

**Competing interests**

RB reports personal fees outside the submitted work from the pharmaceutical companies Grifols and CSL Behring. TG reports personal fees outside the submitted work from the pharmaceutical company CSL Behring, and grants and personal fees from Grifols. CV reports personal fees outside the submitted work from the pharmaceutical companies Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen,
Mundipharma, Novartis, Takeda, Cipla, and grants and personal fees from Grifols. All other authors declare no conflicts of interest.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The COSYCONET study complies with the Declaration of Helsinki and Good Clinical Practice Guidelines and has been approved by the ethics committee of the medical faculty of the Philipps-Universität Marburg, the local ethics committees of the participating centers (a list of all participating study centers can be found here: http://www.cosyconet.net/html/cosyconet/studzent.html) and by the concerned data security authority (data security agency of the federal states of Hesse, Baden-Württemberg, Lower-Saxony, and Saarland). All cohort participants gave their written informed consent.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Gmbh, German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedt Landstr. 1, 85764 Neuherberg, Germany. 2 Institute for Medical Information Processing, Biometrics and Epidemiology (IBE) Ludwig-Maximilians-Universität München (LMU), Marchioninistr. 15, 81377 Munich, Germany. 3 Department of Internal Medicine V – Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Straße 1, 66424 Homburg, Germany. 4 Department of Respiratory Medicine, University of Marburg, University Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Baldingerstraße, 35043 Marburg, Germany. 5 Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336 Munich, Germany. 6 Institute for Biostatistics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 7 Institute of Epidemiology I, Helmholtz Zentrum München, Gmbh, German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedt Landstr. 1, 85764 Neuherberg, Germany.

Received: 12 January 2017 Accepted: 5 April 2017

Published online: 17 April 2017

References
1. Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016;10:72–84.
2. Fregeneone L, Stolk J, Frants RR, Veldhuizen B. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med. 2008;102:786–84.
3. Carrell RW, Lomas DA. Alpha-1-antitrypsin deficiency—a model for congenital diseases. N Engl J Med. 2002;346:45–53.
4. Bergin DA, Reeves EP, Hurley K, Wolfe R, Jameel R, Wolfe R, Lomas DA. Alpha-1-antitrypsin deficiency: model for congenital diseases. N Engl J Med. 2002;346:45–53. 5. Bock J, Bretschneider C, Seidl H, Bowles D, Holle R, Greiner W, König H. Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. Gesundheitswesen. 2015;77.
6. WHO Collaborative Centre for Drug Statistics Methodology/Guidelines for ATC classification and DDD assignment 2010. Oslo: DESTATIS; 2009.
7. Research Institute of the AOK. http://wido.de/arzneimittel.html. Accessed 11 Dec 2016.
8. Kauth C, Hessel F, Hansmeier T, Wasem J, Seitz R. Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation-ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). Gesundheitswesen. 2005;67:376–46.
9. Federal Statistical Office. National Accounts - Compensation per Employee, Gross Wages and Salaries. Wiesbaden: DESTATIS; 2013.
10. Stockley RA. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life. Ann Am Thorac Soc. 2016;13 Suppl 4:S332–5.
11. Huber MB, Wacker ME, Vogelmeier CF, Leidli R. Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. PLoS One. 2015;10:e0123292.
12. Wacker ME, Jorres RA, Schulz H, Heinrich J, Karrasch S, Koch A, Peters A, Leidli R, Vogelmeier C, et al. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med. 2016;111:39–46.
13. Greulich T, Janciauskiene S, Koczulla AR, Ferrarotti I. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107:1400–8.
14. Talercio RM, Chatburn RL, Stoller JK. Knowledge of alpha-1 antitrypsin deficiency among internal medicine house officers and respiratory therapists: results of a survey. Respir Care. 2010;55:322–7.
15. Stoller JK, Aubosousan LS, Kanner RE, Wilson LA, Diaz P, Wise R, Group LR. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2015;12:1796–804.
16. Janus ED, Phillips NT, Carril RW, Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet. 1985;1:152–4.
17. Stockley RA. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life. Ann Am Thorac Soc. 2016;13 Suppl 4:S332–5.
18. Ferrarotti I. Alpha1-antitrypsin deficiency and COPD comorbidity in COPD. PLoS One. 2014;9:e114438.
19. Tattersfield AE, Hubbard PR, O’Callaghan CJ, Renshaw RC, Smith R, lacey M, et al. Reduced health status in chronic obstructive pulmonary disease. Respir Med. 2001;95:960–7.
20. WHO Collaborative Centre for Drug Statistics Methodology/Guidelines for ATC classification and DDD assignment 2010. Oslo: DESTATIS; 2009.
21. Research Institute of the AOK. http://wido.de/arzneimittel.html. Accessed 11 Dec 2016.
22. Kauth C, Hessel F, Hansmeier T, Wasem J, Seitz R. Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation-ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). Gesundheitswesen. 2005;67:376–46.
23. Federal Statistical Office. National Accounts - Compensation per Employee, Gross Wages and Salaries. Wiesbaden: DESTATIS; 2013.
24. Stockley RA. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life. Ann Am Thorac Soc. 2016;13 Suppl 4:S332–5.
25. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–7.
26. WHO Collaborative Centre for Drug Statistics Methodology/Guidelines for ATC classification and DDD assignment 2010. Oslo: DESTATIS; 2009.
27. Research Institute of the AOK. http://wido.de/arzneimittel.html. Accessed 11 Dec 2016.
28. Kauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation-ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). Gesundheitswesen. 2005;67:376–46.
29. Federal Statistical Office. National Accounts - Compensation per Employee, Gross Wages and Salaries. Wiesbaden: DESTATIS; 2013.
30. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55:1204–12.
31. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2016.
32. Kotzsch M, Schlag PM, Daniel J, Dörfler W. Cost of chronic obstructive pulmonary disease (COPD) - an overview. Z Gesundheitswiss. 2013;20:129–37.
33. Greulich T, Nell C, Hoffmann D, Grebe M, Janciauskiene S, Koczulla AR, Vogelmeier CF. The prevalence of diagnosed alpha-1 antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2016;ERJ-00154-02016.
34. Zacherle E, Noone J, Runken M, Blanchette C. Health Care Cost and Utilization Associated With Alpha-1 Antitrypsin Deficiency Among A Cohort of Medicare Beneficiaries With Copd. Value Health. 2015;18:A664.

35. Mullins CD, Wang J, Stoller JK. Major components of the direct medical costs of alpha1-antitrypsin deficiency. Chest. 2003;124:826–31.

36. Manca S, Rodriguez E, Huerta A, Torres M, Lazaro L, Curi S, Pitina P, Miravitlles M. Usefulness of the CAT, LCOPD, EQ-5D and COPSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. COPD. 2014;11:480–8.

37. Chapman KR, Burdon JG, Pitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, et al. Intravenous augmentation treatment and lung density in severe alpha1-antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–8.

38. Köhnlein T, Schmidt-Scherzer K, Greulich T, Bals R. Expertenstellungnahme zur Substitutionstherapie bei Patienten mit Alpha-1-Antitrypsin-Mangel. Pneumologie. 2014;68:492–5.

39. Shermock KM, Gildea TR, Singer M, Stoller JK. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis. COPD. 2005;2:411–8.

40. Sclar DA, Evans MA, Robison LM, Skaeer TL. Alpha1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to alpha1-antitrypsin deficiency: number and costs of years of life gained. Clin Drug Investig. 2012;32:553–60.

41. McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PAB, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, et al. Long-term efficacy and safety of alpha-1 proteinase inhibitor treatment for emphysema caused by severe alpha-1-antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2016;5:51–60.